Navigation Links
New way discovered to predict which breast cancer patients should be treated with anthracyclines
Date:3/25/2010

Barcelona, Spain: An international team of researchers has discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics*.

The research, presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Thursday), is important because, until now, there was conflicting evidence about the best way of predicting response to anthracyclines and it was unclear whether any of the known biomarkers, such as the genes HER2 and TOP2A, were accurate indicators of response to these drugs.

By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines.

After adjusting for additional factors relating to the tumour and its treatment, the researchers found that if patients with CEP17 were treated with anthracyclines, they were approximately two-thirds more likely to survive and to survive without a recurrence of cancer than those who did not receive anthracyclines (recurrence free survival was 67% and overall survival was 63%).

John Bartlett, Professor of Molecular Pathology at the University of Edinburgh (Edinburgh, UK), said: "Our aim was to identify patients for whom anthracyclines provided benefit in terms of disease control and increased survival, and to seek to ensure that future treatment was targeted to this group. Our finding that patients whose tumours have the CEP17 abnormality are more likely to respond to anthracyclines is entirely novel. Subject to confirmation, this suggests that only those patients with CEP17 tumours should receive anthracyclines, thereby enabling other patients who do not have the CEP17 abnormality to avoid a toxic treatment that will
'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-771-129-6986
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2

Related biology news :

1. New, more direct pathways from outside the cell-to-cell nuclei discovered
2. New continent and species discovered in Atlantic study
3. Ancient organisms discovered in Canadian gold mine
4. New golden frog discovered in remote region of Colombia
5. Antioxidant to retard wrinkles discovered by Hebrew University researcher
6. One species entire genome discovered inside anothers
7. New molecules discovered that block cancer cells from modifying cell DNA
8. Chloroplast f and m Thioredoxins Discovered in Nonphotosynthetic Tissues
9. How schizophrenia develops: Major clues discovered
10. New 150 million-year-old crab species discovered
11. Worlds hottest chile pepper discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014 Aware, Inc. (NASDAQ: ... today reported financial results for its third quarter ended September ... 2014 was $6.0 million, an increase of 40% compared to ... in the third quarter of 2014 was $4.1 million compared ... operating income in the current three month period was primarily ...
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... to noise of a diverse range of crustaceans, an international ... families of crustaceans previously assumed to be deaf could detect, ... the Great Barrier Reef, the team collected nearly 700,000 crustaceans, ... each of 34 nights, one light trap was attached to ...
... MD FASEB MARC (Minority Access to Research Careers) ... American College of Sports Medicine (ACSM) Texas Chapter Annual ... awards are meant to promote the entry of underrepresented ... the basic science community and to encourage the participation ...
... ( www.ucr.edu ) -- Ever wonder how much fuel ... window, not using air conditioning or coasting toward stops? ... of Engineering Center for Environmental Research and Technology (CE-CERT) ... is called eco-driving, which refers to providing drivers with ...
Cached Biology News:Rowdy residents warn crustaceans away from perilous reefs 2Research helps drivers cut fuel use 2Research helps drivers cut fuel use 3
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... Diabetes Federation, approximately 400 million people worldwide are living ... 552 million people by 2030.  The global market for ... In 2012 approximately 330,000 people worldwide died from pancreatic ... of death due to cancer in the ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014  aTyr ... today that rare disease expert John C. McKew ... Dr. McKew brings more than two decades of expertise ... National Institutes of Health, Wyeth Research and Genetics Institute, ... lead aTyr,s efforts to expand and translate its novel ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... CITY, Oct. 7 Great Basin Scientific, Inc., ... diagnostic solutions, today announced it had closed a ... in the,funding for this round., The new ... the spring of,2009 as it completes the design ...
... List for Fourth Consecutive Year, INDIANAPOLIS, ... one of the magazine,s Top 500 innovative ... a handful of companies in the biotech,and ... No. 86, in the 2008 report,outperformed others ...
... Vical Incorporated (Nasdaq:,VICL) and AnGes MG, Inc., ... mutual interest to license the development and marketing,rights ... to AnGes. AnGes,plans to conduct due diligence on ... to negotiate terms and conditions potentially leading,to a ...
Cached Biology Technology:Great Basin Scientific, Inc. Closes $3.9 Million in Equity Funding 2InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List 2Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program 2
Human/Rat Neurogenin-2 MAb (Clone 7G4) Protein Family: Neural Crest Cell Markers, Transcription Factors...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Mouse TREM-2 Affinity Purified Polyclonal Ab...
Biology Products: